ABL1 and hepatocellular carcinoma: MiR‐30e‐induced apoptosis and benefited imatinib treatment in chronic myeloid leukaemia via inhibition of BCR‐ABL 25 and repressed proliferation of hepatocellular carcinoma cells via targeting P4HA1 26.